SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs lead product, DefenCath, could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and revenue. Traders dispute how definitive DaVitas preliminary outlook is, pointing to CMSs published rate estimates and arguing that greater use could offset lower reimbursement.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its upcoming earnings, with traders debating whether growth will support the stock after a volatile pullback. Bullish traders expect a strong report, while others cite valuation and unverified concerns about security issues in third-party apps as reasons for caution.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas fiscal Q4 results are driving discussion: a modest earnings beat and resilient payment activity are tempered by a slower-growth outlook, prompting a sell-the-news reaction. Bulls point to durable consumer spending and cross-border activity, while skeptics argue the results and guidance fall short of expectations.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing RRP treatment has put pressure on Precigens PAPZIMEOS, prompting debate over how much competition could affect its sales. Traders are split: some see the rival as a serious threat, while others emphasize Precigens full approval and commercial head start, alongside questions about Inovios accelerated-approval requirements and ability to launch.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

A sharp Nasdaq and tech-sector selloff has driven attention to TQQQ, with traders citing worries about AI spending and earnings alongside inflation, interest-rate, and geopolitical risks. The community is split between buying the steep dip for a possible rebound and warning that further losses may follow.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is drawing attention as a listed treasury proxy for Hyperliquids HYPE token, with traders linking its swings to HYPEs rally and the broader ecosystems growth. Bulls see room for a catch-up move or short squeeze, while bears point to share issuance and dilution as reasons PURR has lagged the token.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lillys strong quarterly results and raised revenue outlook, driven by demand for Mounjaro and Zepbound, are fueling a rally to record highs. Bulls point to continued growth in its obesity-drug franchise, while skeptics highlight the trimmed profit outlook, rich valuation, and weaker-than-expected Foundayo sales.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has climbed to a 52-week high as traders anticipate its Q3 results and continued BRIUMVI growth; some attribute the move to earnings expectations, while others speculate about a buyout or short covering. No acquisition has been confirmed, and the earnings date remains unconfirmed.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Better-than-expected quarterly results, led by strong parks performance and improving streaming profitability, have renewed optimism about Disneys turnaround under new leadership. Traders are debating whether those business trends can lift the stock after its muted, range-bound performance.

Internet Computer (ICP) is a cryptocurrency launched in 2021. Internet Computer has a current supply of 558,194,898.12638538. The last known price of Internet Computer is 2.5370221 USD and is up 5.18 over the last 24 hours. It is currently trading on 447 active market(s) with $63,762,762.22 traded over the last 24 hours. More information can be found at https://internetcomputer.org/.

Internet Computer

Discussion centers on ICPs sovereign-cloud and AI infrastructure ambitions, including posts about a Pakistan national chat app beta and potential government adoption. Bulls view these as signs of real-world utility, while skeptics point to weak adoption, token-supply concerns and prolonged underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence

Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.read more...

Satellos Bioscience Inc. (NASDAQ:MSLE) Given Average Rating of "Moderate Buy" by Analysts

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Guggenheim

Guggenheim began coverage on shares of Satellos Bioscience in a research note on Tuesday. They issued a "buy" rating and a $23.00 price objective for the company...

Satellos Bioscience (NASDAQ:MSLE) Downgraded by Wall Street Zen to "Strong Sell"

Wall Street Zen downgraded Satellos Bioscience from a "sell" rating to a "strong sell" rating in a report on Saturday...

Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) has been assigned an average rating of "Hold" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Satellos Bioscience in a research report on Monday. They set an "outperform" rating and a $20.00 price target on the stock...

Q2 EPS Estimate for Satellos Bioscience Increased by Analyst

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Satellos Bioscience in a report issued on Monday, March 30th. HC...

FY2030 Earnings Forecast for MSLE Issued By HC Wainwright

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research note issued to investors on Monday, March 30th. HC Wainwright analyst A. He expects that the company will earn $0.34 per share...

Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00

HC Wainwright boosted their price objective on shares of Satellos Bioscience from $1.20 to $11.00 and gave the stock a "buy" rating in a research report on Monday...

Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.36...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>MSLE stock&nbsp;was down about 2%&nbsp;in overnight trading heading into Tuesday.</li><li>The company completed a $57.2 million public offering to fund its lead drug, SAT-3247, and other research into muscle diseases.</li><li>Early data for SAT-3247 is expected in the second quarter of 2026, following encouraging adult safety results.</li></ul>Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday before ending the session more than 3% lower and dipping over 8% in after-hours trading.Investor sentiment took a hit after the company revealed it had completed an equity raise to fund its Duchenne muscular dystrophy (DMD) program and broader muscle disease research.&nbsp;<h2 class="st-heading-2">MSLE Wraps Up Equity Raise</h2>Satellos said it has completed its underwritten public offering, raising about $57.2 million before fees. The deal included roughly 5.2 million common shares, along with pre-funded warrants for some investors. The <a href="https://stocktwits.com/symbol/MSLE">shares of Satellos</a> were sold at $10.1 each. The stock is also listed on the Toronto Stock Exchange under the MSCL ticker.The company said the funds will mainly support research and development, with a focus on advancing SAT-3247, its lead drug candidate, into mid and late-stage clinical trials. Some of the money will also be used to explore additional muscle-related diseases and support early-stage research programs.Ahead of the Nasdaq listing, Satellos carried out a 1-for-12 share consolidation in late January. This reduced the total number of shares from about 185.5 million to roughly 15.5 million, helping the stock meet Nasdaq’s listing requirements.<h2 class="st-heading-2">How SAT-3247 Works</h2>SAT-3247 is an oral drug designed to help the body repair and regenerate muscle by targeting a protein called AAK1, which plays a role in muscle stem cell signaling. Unlike gene therapies, SAT-3247 does not depend on fixing the dystrophin gene, meaning it could potentially work for a wide range of Duchenne patients, regardless of their specific genetic mutation.In December, Satellos received FDA clearance and approvals from global regulators to begin a Phase 2 clinical study of SAT-3247 in 51 children with Duchenne. The study will test safety and measure changes in muscle strength and function. The company expects early trial results in the second quarter of 2026. Earlier studies in adults showed that the drug was well tolerated and associated with improvements in grip strength over a 28-day treatment period.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Satellos Bioscience was ‘neutral’ amid ‘extremely low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/msle_ss_png_8d0bdc8b59.webp" alt="msle ss.png" width="973" height="142"><figcaption>MSLE sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure>One user said the company’s “Clinical results should be pretty stellar.”<stembedurl>https://stocktwits.com/bruceleeboy/message/644522213</stembedurl>Another user said, “It looks like all went well with the listing. Great work. Let’s see if we&nbsp; get something going this Spring.”<stembedurl>https://stocktwits.com/PennyScam/message/644421647</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Satellos Bioscience Inc. (MSLE) opened more than 10% above their offering price in the company’s Nasdaq debut on Monday. (Photo credit: Getty Images)

SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.70
Prev Close	$6.82
Open	$6.68
Dividend Yield	0.00%
50-Day Moving Average	$8.28
Beta	0.29
Avg. Volume	53,602.96
PE Ratio	-3.38

52-Week High	$13.39
52-Week Low	$5.30
Market Capitalization	$142.15M
EPS (Annual)	-$1.70
Price to Book	2.33
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

MSLE Fundamentals